Dimerix' (ASX:DXB) interim analysis imminent. Interview with CEO Dr. Nina Webster.
We spoke with Dr. Nina Webster, CEO of Dimerix (ASX: DXB) about the important Phase 3 study of DMX-200 in a rare kidney disease called Focal Segmental Glomerulosclerosis.
This study reads out its first interim analysis in mid-March 2024. A second analysis later in the trial can potentially open up accelerated approval of the drug.